AQUILON PHARMACEUTICALS: what changed
What changed
AQUILON PHARMACEUTICALS
NACE 72.101, Research and development on biotechnology
filed annual accounts (NBB)
Net result for the year
-€444,073
2024 · -€913,660+€469,587
Equity
€4.3m
2024 · €1.3m+€3.0m
Cash
€389,042
2024 · €208,427+€180,615
Balance sheet total
€11.1m
2024 · €10.3m+€799,878
Largest movements
Assets
- Intangible fixed assets +€612,651
up €612,651 (+6.4%), from €9.6m to €10.2m
- Cash +€180,615
up €180,615 (+86.7%), from €208,427 to €389,042
mainly Contributions, distributions and other (+€3.4m) and Debts after one year (+€1.1m)
Equity and liabilities
- Short-term financial debts -€3.1m
down €3.1m (-100%), from €3.1m to €0
- Contributions +€3.0m
up €3.0m (+118%), from €2.5m to €5.5m
- Debts after one year +€1.1m
up €1.1m (+27.9%), from €4.1m to €5.2m
- Trade debts -€131,040
down €131,040 (-9.3%), from €1.4m to €1.3m
Income statement
- Staff costs -€320,474
down €320,474 (-30.8%), from €1.0m to €720,306
- Gross operating margin +€265,483
up €265,483 (+26.8%), from €991,768 to €1.3m
- Depreciation +€140,661
up €140,661 (+28.5%), from €493,288 to €633,948
- Financial income +€18,098
up €18,098 (+2,282%), from €793 to €18,891
Change in the result, 2024 to 2025
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2024
-€913,660
Gross operating margin
+€265,483
Staff costs
+€320,474
Depreciation
-€140,661
Other operating charges
+€11,236
Financial income
+€18,098
Financial charges
+€4,421
Taxes
-€9,464
Result 2025
-€444,073
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
-€41,466
Investment
-€1.2m
Financing
+€1.4m
Cash 2024
€208,427
From operations (derived)
-€41,466
Net result for the year
-€444,073
Depreciation
+€633,948
Receivables after one year
+€26,644
Receivables within one year
-€60,074
Smaller working-capital items
+€10,915
Trade debts
-€131,040
Other debts
-€45,082
Accrued charges and deferred income
-€32,705
Investment (derived)
-€1.2m
Investment in fixed assets (net)
-€1.2m
Financing
+€1.4m
Debts after one year
+€1.1m
Current portion of long-term debt
+€45,695
Short-term financial debts
-€3.1m
Contributions, distributions and other
+€3.4m
Cash 2025
€389,042
brings cash intakes cash out
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €10,306,004 | €11,105,882 | +€799,878 | +7.8% |
| Formation expenses | 20 | €9,878 | €9,878 | = | 0.0% |
| Fixed assets | 21/28 | €9,686,898 | €10,276,871 | +€589,973 | +6.1% |
| Intangible fixed assets | 21 | €9,626,123 | €10,238,774 | +€612,651 | +6.4% |
| Tangible fixed assets | 22/27 | €26,483 | €8,992 | -€17,491 | -66.0% |
| Plant, machinery and equipment | 23 | €23,704 | €7,766 | -€15,938 | -67.2% |
| Furniture and vehicles | 24 | €2,779 | €1,226 | -€1,554 | -55.9% |
| Financial fixed assets | 28 | €34,292 | €29,105 | -€5,186 | -15.1% |
| Current assets | 29/58 | €609,227 | €819,132 | +€209,905 | +34.5% |
| Amounts receivable after more than one year | 29 | €304,073 | €277,429 | -€26,644 | -8.8% |
| Other amounts receivable | 291 | €304,073 | €277,429 | -€26,644 | -8.8% |
| Amounts receivable within one year | 40/41 | €87,397 | €147,471 | +€60,074 | +68.7% |
| Trade receivables | 40 | €6,795 | €115,500 | +€108,705 | +1,600% |
| Other amounts receivable | 41 | €80,602 | €31,971 | -€48,632 | -60.3% |
| Cash at bank and in hand | 54/58 | €208,427 | €389,042 | +€180,615 | +86.7% |
| Deferred charges and accrued income | 490/1 | €9,330 | €5,190 | -€4,140 | -44.4% |
| Total equity and liabilities | 10/49 | €10,306,004 | €11,105,882 | +€799,878 | +7.8% |
| Equity | 10/15 | €1,296,242 | €4,254,081 | +€3.0m | +228% |
| Contributions | 10/11 | €2,516,289 | €5,486,277 | +€3.0m | +118% |
| Capital | 10 | €2,516,289 | €5,486,277 | +€3.0m | +118% |
| Issued capital | 100 | €2,516,289 | €5,486,277 | +€3.0m | +118% |
| Profit (loss) carried forward | 14 | -€1,400,812 | -€1,394,885 | +€5,927 | +0.4% |
| Investment grants | 15 | €180,765 | €162,689 | -€18,077 | -10.0% |
| Amounts payable | 17/49 | €9,009,762 | €6,851,801 | -€2.2m | -24.0% |
| Amounts payable after more than one year | 17 | €4,105,267 | €5,249,657 | +€1.1m | +27.9% |
| Financial debts | 170/4 | €4,105,267 | €5,249,657 | +€1.1m | +27.9% |
| Amounts payable within one year | 42/48 | €4,871,498 | €1,601,851 | -€3.3m | -67.1% |
| Current portion of amounts payable after more than one year | 42 | €132,892 | €178,587 | +€45,695 | +34.4% |
| Financial debts | 43 | €3,145,995 | €0 | -€3.1m | -100% |
| Credit institutions | 430/8 | €3,145,995 | €0 | -€3.1m | -100% |
| Trade debts | 44 | €1,408,642 | €1,277,602 | -€131,040 | -9.3% |
| Suppliers | 440/4 | €1,408,642 | €1,277,602 | -€131,040 | -9.3% |
| Taxes, remuneration and social security | 45 | €115,932 | €122,707 | +€6,775 | +5.8% |
| Taxes | 450/3 | €9,954 | €15,655 | +€5,701 | +57.3% |
| Remuneration and social security | 454/9 | €105,978 | €107,053 | +€1,075 | +1.0% |
| Other amounts payable | 47/48 | €68,038 | €22,956 | -€45,082 | -66.3% |
| Accrued charges and deferred income | 492/3 | €32,997 | €292 | -€32,705 | -99.1% |
| Remuneration, social security and pensions | 62 | €1,040,780 | €720,306 | -€320,474 | -30.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €493,288 | €633,948 | +€140,661 | +28.5% |
| Other operating charges | 640/8 | €16,292 | €5,056 | -€11,236 | -69.0% |
| Gross operating margin | 9900 | €991,768 | €1,257,251 | +€265,483 | +26.8% |
| Operating profit (loss) | 9901 | -€558,591 | -€102,059 | +€456,532 | +81.7% |
| Financial income | 75/76B | €793 | €18,891 | +€18,098 | +2,282% |
| Recurring financial income | 75 | €793 | €18,891 | +€18,098 | +2,282% |
| Financial charges | 65/66B | €406,062 | €401,641 | -€4,421 | -1.1% |
| Recurring financial charges | 65 | €406,062 | €401,641 | -€4,421 | -1.1% |
| Profit (loss) for the period before taxes | 9903 | -€963,860 | -€484,809 | +€479,051 | +49.7% |
| Income taxes | 67/77 | -€50,200 | -€40,736 | +€9,464 | +18.9% |
| Profit (loss) for the period | 9904 | -€913,660 | -€444,073 | +€469,587 | +51.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€913,660 | -€444,073 | +€469,587 | +51.4% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.